iBio, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100.0K | $400.0K | $225.0K | $0 | $1.9M | $2.4M | $1.6M | $2.0M |
| Cost of Revenue | — | — | — | — | $216.0K | $1.5M | $703.0K | — |
| Gross Profit | — | — | — | — | $2.2M | $909.0K | $935.0K | — |
| Gross Margin | — | — | — | — | 115.0% | 38.3% | 57.1% | — |
| Operating Expenses | ||||||||
| Research & Development | $19.6M | $8.3M | $5.2M | $10.3M | $9.8M | $10.0M | $3.6M | $5.5M |
| SG&A Expense | $10.6M | $10.7M | $11.7M | $19.0M | $21.8M | $22.0M | $11.4M | $12.3M |
| Operating Income | $-35.1M | $-18.6M | $-16.6M | $-29.3M | $-29.7M | $-31.1M | $-14.0M | $-15.8M |
| Operating Margin | -35,141.0% | -4,650.5% | -7,392.9% | — | -1,576.3% | -1,312.1% | -854.9% | -782.4% |
| Interest Expense | — | — | — | $83.0K | $1.4M | $2.5M | $2.5M | $1.9M |
| Pretax Income | $-33.0M | $-18.4M | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-33.0M | $-18.4M | $-24.9M | $-65.0M | $-50.3M | $-23.2M | $-16.4M | $-17.6M |
| Net Margin | -33,044.0% | -4,594.3% | -11,069.8% | — | -2,670.0% | -978.8% | -1,003.6% | -871.8% |
| EPS (Basic) | $-0.32 | $-1.75 | $-0.65 | $-1.77 | $-0.10 | $-0.05 | $-0.01 | $-0.02 |
| EPS (Diluted) | $-0.32 | $-1.75 | $-0.65 | $-1.77 | $-0.10 | $-0.05 | $-0.01 | $-0.02 |
| Shares Outstanding (Basic) | 104.1M | 10.5M | 38.3M | 36.7M | 523.3M | 469.5M | 10.82B | 1.45B |
| Shares Outstanding (Diluted) | 104.1M | 10.5M | 38.3M | 36.7M | 523.3M | 469.5M | 10.82B | 1.45B |
| Dividends Per Share | — | — | — | — | — | — | — | — |